Completed PHASE3 INTERVENTIONAL 2-arm NCT00206674

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Phase 3 Randomized, Double-Blind, Placebo Controlled Induction Study of Sargramostim (Leukine®) in Patients With Active Crohn's Disease

Sponsor: Genzyme, a Sanofi Company

Conditions Crohn Disease

Interventions Placebo Sargramostim (Leukine)

Updated 7 times since 2017 Last updated: Dec 2, 2013 Started: Sep 30, 2004 Primary completion: Jun 30, 2006 Completion: Jun 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Crohn Disease, this trial is completed. The trial is conducted by Genzyme, a Sanofi Company and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Ballarat, Australia , Basel, Switzerland , Bern, Switzerland , Brisbane, Australia , Bristol, United Kingdom , Buenos Aires, Argentina , Cardiff, United Kingdom , Christchurch, New Zealand , Concord, Australia and 47 more locations